Monday, July 8, 2019

MissionIRNewsBreaks – Pressure BioSciences Inc.’s (PBIO) PCT Platform Highlighted at Spectrometry Conference


Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences industry, recently announced that its patented pressure cycling technology (“PCT”) platform was featured in 15 independent scientific presentations at the annual conference of the American Society of Mass Spectrometry (“ASMS”) (http://ibn.fm/vLiCW). An article further discussing the company reads, “The ASMS annual meeting is a highly reputable conference attended by more than 10,000 scientists from around the world. It is a showcase event for new research and scientific findings that has been held every year since 1953. . . . This year’s PCT-involving presentations spanned a range of applications — from cancer research to molecular biology and biomarker discovery. Of the 15 presentations, nine focused on the importance of PBIO’s PCT platform in cancer research. Three of these presentations put emphasis on the use of streamlined sample preparation protocols and systems featuring Pressure BioSciences’ Barocycler 2320EXT instrument and its associated and proprietary MicroTubes.”

To view the full article, visit http://ibn.fm/0Yf6F

About Pressure BioSciences Inc.

Pressure BioSciences (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold Inc. to allow entry into the biologics contract research services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html